Evgen Pharma's SFX-01 has positive effects for treating a rare cancer
(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome. The Cheshire, England-based clinical s...
Source: marketscreener.com